オノ　マキコ   ONO Makiko   小野　麻紀子    所属   医学部 医学科（東京女子医科大学病院）    職種   准教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Addressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancers.
掲載誌名	正式名：ESMO open 略　 称：ESMO Open ISSNコード：20597029/20597029
巻・号・頁	9(8),pp.103659
著者・共著者	N Hayashi, M Ono, I Fukada, M Yamazaki, N Sato, M Hosonaga, X Wang, K Kaneko, H Arakawa, E Habano, A Kuga, A Kataoka, A Ueki, K Kiyotani, A Tonooka, K Takeuchi, T Kogawa, S Kitano, T Takano, M Watanabe, S Mori, S Takahashi
発行年月	2024/08
概要	BACKGROUND:Adolescents and young adults (AYAs) represent a small proportion of patients with cancer. The genomic profiles of AYA patients with cancer are not well-studied, and outcomes of genome-matched therapies remain largely unknown.PATIENTS AND METHODS:We investigated differences between Japanese AYA and older adult (OA) patients in genomic alterations, therapeutic evidence levels, and genome-matched therapy usage by cancer type. We also assessed treatment outcomes.RESULTS:AYA patients accounted for 8.3% of 876 cases. Microsatellite instability-high and/or tumor mutation burden was less common in AYA patients (1.4% versus 7.7% in OA; P = 0.05). However, BRCA1 alterations were more common in AYA patients with breast cancer (27.3% versus 1.7% in OA; P = 0.01), as were MYC alterations in AYA patients with colorectal cancer (23.5% versus 5.8% in OA; P = 0.02) and sarcoma (31.3% versus 3.4% in OA; P = 0.01). Genome-matched therapy use was similar between groups, with overall survival tending to improve in both. However, in AYA patients, the small number of patients prevented statistical significance. Comprehensive genomic profiling-guided genome-matched therapy yielded encouraging results, with progression-free survival of 9.0 months in AYA versus 3.7 months in OA patients (P = 0.59).CONCLUSION:Our study suggests that tailored therapeutic approaches can benefit cancer patients regardless of age.
DOI	10.1016/j.esmoop.2024.103659
PMID	39137480